

## CORRIGENDUM

# Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab

D. Lenihan, T. Suter, M. Brammer, C. Neate, G. Ross & J. Baselga

*Ann Oncol* 2012; 23: 791–800 (doi: 10.1093/annonc/mdr294)

In the original article, the disclosure was incomplete. This has now been updated to add the statement for J. Baselga:

JB is the consultant and on the advisory board for Roche and Novartis.